Related Experiment Videos
Priapism. From Priapus to the present time.
1Division of Urology, University of Western Ontario, London, Ontario, Canada.
The Urologic Clinics of North America
|June 14, 2001
Summary
Pharmacotherapeutic advances have transformed erectile dysfunction (ED) treatment, reducing priapism risk from injections. New research aims to improve understanding and management of priapism, a condition potentially linked to drug use and trauma.
Area of Science:
- Urology
- Pharmacology
- Andrology
Background:
- Pharmacotherapeutic options for erectile dysfunction (ED) have significantly evolved.
- Intracavernous injections, initially papaverine, led to increased priapism cases.
- Widespread oral ED agents have reduced priapism incidence related to injections.
Purpose of the Study:
- To review the current landscape of priapism management.
- To emphasize the urologist's role in diagnosing and treating priapism.
- To highlight the importance of understanding corporal oxygenation for treatment decisions.
Main Methods:
- Review of pharmacotherapeutic advancements in ED treatment.
- Discussion of priapism etiology, including recreational drug use and trauma.
- Emphasis on diagnostic assessment, including corporal oxygenation status.
- Outline of treatment strategies based on priapism type (ischemic vs. non-ischemic).
Main Results:
- Low-flow ischemic priapism necessitates rapid intervention with alpha-agonists.
- Non-ischemic priapism allows for more conservative management approaches.
- Increasing incidence of priapism linked to recreational drug use and perineal trauma.
Conclusions:
- Early assessment of corporal oxygenation is crucial for optimal priapism management.
- Understanding underlying medical conditions and risk factors is essential.
- Further research into priapism pathophysiology may yield etiology-specific treatments for timely detumescence.